31 results about "Dietary fat" patented technology

The embodiments relate to fat emulsion structures based on both an aqueous and non-aqueous glycerin component as the primary aqueous component in which the fat emulsion can create a wide range of viscosities that mimic fat structures similar to cream, or all the way to hardened fat structures like Trans Fat. The fat emulsion can be added to a wide group of foods that use a monosaccharide or disaccharide as the basis for its sweetener component, can lower the sugar content of foods, can improve mouth feel while lowering the fat content in high fat foods, can add a balance of dietary fats and fiber to foods, and can add antioxidant content to food products.

The embodiments relate to fat emulsion structures based on both an aqueous and non-aqueous glycerin component as the primary aqueous component in which the fat emulsion can create a wide range of viscosities that mimic fat structures similar to cream, or all the way to hardened fat structures like Trans Fat. The fat emulsion can be added to a wide group of foods that use a monosaccharide or disaccharide as the basis for its sweetener component, can lower the sugar content of foods, can improve mouth feel while lowering the fat content in high fat foods, can add a balance of dietary fats and fiber to foods, and can add antioxidant content to food products. The fat emulsion also can be used as a taste masking composition to mask the taste of unpalatable active ingredients or unpalatable components that may be added to the emulsion.

This invention relates to novel N-Acyl and N-Alkyl modified quaternary ammonium polysaccharide fibers, or both N-Acyl and N-Alkyl modified quaternary ammonium polysaccharide fibers and pharmaceutical compositions comprising the modified fibers. Further the invention relates to processes for using such modified polysaccharide fibers to lower cholesterol, to lower a mammal's absorption and metabolic use of dietary fat as calories, or as a dietary fiber supplement. The polysaccharides may be modified with quaternary ammonium side chains that are capable of sequestering bile salts while other portions of the polysaccharide absorbs substantial amounts of oils or fats while dissipating the modified polysaccharide and oil complex in aqueous digestive fluids and solids. The N-Acyl modified polysaccharide intermediates are also useful to lower cholesterol, lower the absorption and metabolism of dietary fat, and as a simple dietary fiber.

The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. The methods comprise the step of orally administering to a mammal, such as a human, a therapeutically effective amount of one or more fat-binding polymers. The administration of the fat-binding polymer of the invention facilitates the removal of fat from the body prior to digestion, with minimal side effects and low toxicity. In a preferred embodiment, the one or more fat-binding polymers are administered in combination with one or more lipase inhibitors, for example, lipstatin and tetrahydrolipstatin.

This invention relates to fat containing consumable food products comprising α-cyclodextrin. The food products have reduced levels of bioavailable fat but have substantially the same fat, cholesterol and caloric content as a like food without α-cyclodextrin. The invention also relates to methods for reducing the bioavailability of fats in fat containing food products without reducing caloric intake as determined by bomb calorimetry and to methods for increasing high density lipoproteins in a subject and reducing or controlling weight by administering the food products of this invention.

Composition and method comprising complex carbohydrates and dietary fats for reducing, delaying or preventing alcohol intoxication.

The present invention relates to a method for lowering risk of cardiovascular diseases in human, particularly for lowering low density lipoprotein cholesterol (LDL-C) concentration and oxidative stress level while maintaining sufficient high density lipoprotein cholesterol (HDL-C) concentration in human, and to a dietary formulation and a fat or fat blend suitable for human consumption for resulting in the same. The method is by way of controlling daily dietary fat and antioxidants consumption so that: daily dietary fat accounts for 20-40% of the total daily dietary energy intake; 10-20% wt of the fatty acids in daily dietary fat are saturated fatty acids (SFAs); 20-35% wt of the fatty acids in daily dietary fat are polyunsaturated fatty acids (PUFAs); 45-70% wt of the fatty acids in daily dietary fat are monounsaturated fatty acids (MUFAs); and the ratio of antioxidants to polyunsaturated fatty acids (PUFAs) in daily dietary fat is ranging from about 15-70 ppm antioxidants/% wt PUFAs.

The invention provides a preparation method of a feeding functional fat product capable of reducing weight of pork leaf lard. By adding conjugated linoleic acid to pig dietary fat, carcass compositionof a pig is improved obviously, thickness of a fat layer is reduced, eye muscle area is increased, and lean meat percentage is increased; meanwhile, content of conjugated linoleic acid of pork is increased, benefits to human health are realized, and residues are avoided; further by means of conjugated linoleic acid, color of pork products can be improved, marbling score is increased, intramuscular fat content is increased, the shelf life of meat is prolonged, and pork quality is improved accordingly.

This invention discloses a method for similarity evaluation of dietary fat, including, establishing the evaluation model and quantifying the differences between dietary fat and human milk fat. The evaluation model provided by the present invention can comprehensive highlight of similarity without the influence of the content of indexes, integrated quantitative differences between dietary fat and human milk fat using similarity coefficient. The similarity evaluation method can grade human milk fat objectively and evaluate the similarity of dietary fat to human milk fat through the grading evaluation. Thus the invention provides a comprehensive method to evaluate the similarity of dietary fat to human milk fat.

The invention discloses a composite health sweetener prepared by a biological imitative innovation technology. In one embodiment, the sweetener comprises the following ingredients of: by weight, 1-5% of sucralose, 15-30% of stevioside, 30-35% of high-quality sugar alcohol and 35-45% of oligosaccharides. In another embodiment, the sweetener comprises the following ingredients of: by weight, 2-5% of sucralose, 20-35% of stevioside, 10-20% of xylitol and 50-60% of glucose. It is known through the ingredient analysis of the sweetener that the sweetener is safe to use, has a pure taste, has a taste of cane sugar and has a very sweet taste similar to the taste of cane sugar; the sweetener has high sweetness and the sweetness of 1 kg of the sweetener is equivalent to that of 50 kg of cane sugar; the sweetener has low sugar and low calorie or has no sugar or zero calorie such that the content and heat of dietary fat are reduced; the sweetener is carious tooth resistant such that it will not be harmful to teeth due to its sweet taste in the way cane sugar will be when children eat a food which is prepared by using the sweetener as a sweetening agent; the sweetener has excellent solubility and high quality, is fine, can promote propagation of bifidobacteria in an intestinal tract and has a health care function; and the sweetener is low in price, and the price of the sweetener with the same sweetness is greatly lower than that of cane sugar and is probably 50% of the price of cane sugar.

The invention provides application of sanggenone D in preparation of a medicine or pharmaceutical composition for treating hyperlipidemia and/or obesity. The invention develops a novel strategy for preparing medicines for treating hyperlipidemia and/or obesity, namely a medicine for treating hyperlipidemia and/or obesity prepared from sanggenone D, monomeric compounds of sanggenone D, or plant extract or dietary supplement containing the compounds. Digestion and absorption of dietary fat can be further reduced by strongly inhibiting pancrelipase, the effects of reducing blood fat and losing weight are achieved, and the IC50 of the sanggenone D inhibiting pancrelipase can reach 0.77micron. In addition, due to combined use of the sanggenone D and other drugs or natural products, the drug effects are further achieved, and the sanggenone D has wide application prospects and a huge market value.

This invention relates to novel N-acyl modified polysaccharides and pharmaceutical compositions comprising the modified polysaccharides and comprising dietary calcium as a mixture or as a salt. Further the invention relates to processes for using such compounds to inhibit lipases, to lower cholesterol, to lower the absorption of dietary fat, or as a dietary fiber supplement. In a preferred aspect of the invention the modified polysaccharides are capable of absorbing substantial amounts of oils or fats while dissipating in an aqueous solution. The invention also relates to a non-absorbable and essentially non-digestible polysaccharide fiber composition that is useful as a weight loss composition.

The invention provides an application of phillyrin in preparation of digestants, namely an application of phillyrin in preparation of drugs promoting pancreatic lipase activity. Phillyrin has effect of promoting pancreatic lipase activity to quicken lipodieresis of dietary fat, improve absorption of fat and lipidic solubility nutriment and reduce malnutrition symptom. According to experiment in vivo, content of pancreatic lipase activity is increased to 146. 43% after 800 mu m g/mL of phillyrin solution is added. As proved by mechanism and experiment of promoting pancreatic lipase activity by phillyrin, phillyrin has competitive promotion function to pancreatic lipase activity.

The invention discloses a probiotic herbal beverage with intestine moistening and oil discharging effects and a preparation method thereof, and relates to the field of probiotic herbal beverages. Theherbal beverage comprises the following raw materials in parts by weight: 5-40% of a sugar alcohol solution, 1-10% of dietary fibers, 1-10% of a fungus extract, 1-10% of a white kidney bean extract, 1-10% of a Compton tea stock solution, 0.1-5% of apple original vinegar, 0.1-5% of noni juice, 0.1-3% of lactobacillus plantarum Lp90, and the balance water. The probiotic herbal beverage takes sugar alcohol, dietary fibers, fungus extract, white kidney bean extract, Compton tea stock solution and lactobacillus plantarum Lp90 as main functional components, and the main mechanism is that the functional components can effectively increase probiotics in the intestinal tract, and wrap the oil absorbed in the intestinal tract while promoting intestinal peristalsis so as to remarkably reduce the digestion and absorption of dietary fat in the body, and has a remarkable effect of moistening intestines and relaxing bowels.

The use of sucrose polyester containing behenate fatty acid chains as a non-absorbable fat marker to determine total dietary fat absorption by the digestive tract of a subject. A test food for use in measuring fat absorption contains a non-absorbable fat and a dietary fat. The method is useful for diagnostic testing for diagnosing malabsorption of dietary fat by the digestive tract of the subject, and impairment of dietary fat digestion in the subject.

A device composed of a plurality of beeswax microspheres are contained within a digestible capsule intended for the alimentary tract of the mammal. A method in which the device is ingested orally into the digestive system. A method in which digestive enzymes remove the outside capsule and beeswax microspheres are then dispersed within the gastrointestinal tract. The beeswax microsphere is then able to come in contact with free fats, lipids, cholesterol and lipophillic toxins within the gut and absorb them into the lumen of the microsphere. The beeswax microsphere along with all the fats, lipids, cholesterol and lipophillic toxins contained within the microsphere transits through the remainder of the gut undigested and are eventually excreted from the rectum and bowel by fecal elimination.

Supplement for use in animal feed, which consists of a composition intended for animal feed that allows the digestibility of dietary fat to be improved and same to be used at the metabolic level without overloading the hepatic system, comprising a combination of 0.5-5.5% by weight botanicals, 3.0-18.0% by weight vitamins and provitamins, 12.0-25.0% by weight lecithins, 3.0-10.0% by weight sorbitan esters, and 45.0-65.0% antioxidant and adsorbent excipient.

A ketone measurement and analysis system provides various features for enabling health program participants to interpret their ketone measurements, such as breath acetone measurements. One such feature breaks down ketone measurements into causal components. For example, the system may generate and display an estimate of how much of a participant's ketone measurement is attributable to stored fat metabolism versus consumption of a “confounding substance” such as dietary fat and/or exogenous ketones. The system may also estimate the contributions of specific confounding substances, and/or the contributions of other factors or events (such as exercise, interrupted sleep, a missed medication, etc.) that affect ketone levels. Another feature involves the generation and display of target ketone levels that are personalized for the participants. The system may generate the measurement breakdowns and target ketone levels by applying data mining algorithms to aggregated data of many program participants.

Composition comprising (optionally processed) edible parts of an okra plant species for use in reducing dietary fat absorption in a subject or for use in treating or preventing obesity and/or for use in treating or preventing a metabolic disease such as metabolic syndrome, or for managing the weight of a subject, by binding dietary fat in the subject's stomach.

The invention relates, firstly, to a method for eliminating ingested dietary fats before they are assimilated by the body, using an AGP extracted from cactus mucilage. Said AGP can be in any galenic or commercial form which is solid or dissolved in water. The invention also discloses the method of extracting this AGP from the mucilage of a cactus of the Platyopuntia genus, by means of a process which makes it possible to preserve the polysaccharide-protein association, which association is responsible for the observed activity.